Updates on First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3-7, 2011

Alexios S Strimpakos¹, Kostas N Syrigos¹, Muhammad Wasif Saif²

¹Oncology Unit, Third Department of Medicine, Sotiria General Hospital. Athens, Greece.
²Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital. New York, NY, USA

Summary

Despite the extensive research, mounting knowledge in the cancer field and enormous investments, pancreatic cancer remains a rather incurable disease with aggressive natural course and high mortality rate. The very slow progress is a result of the complex pathogenesis of this disease, which prevents us from targeting the culprit and making a step forward. Therefore, the field is still unexplored and this is a real challenge and opportunity for new ideas and novel approaches. In this paper, we will present the most interesting studies in the first line pancreatic cancer setting, presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting. While there are few studies testing the role of combining the cytotoxic S-1 and gemcitabine, the majority of the studies are examining the safety and impact of adding to the classic gemcitabine treatment novel molecular agents which target key pathways or overexpressed proteins.

What Did We Know Before the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting?

Pancreatic cancer is a lethal malignancy which is affecting many patients in the Western mostly countries. Unfortunately, there is often lack of warning signs or early symptoms; therefore, more than 2/3 of patients present at a late stage at the time of diagnosis [1]. Advanced disease precludes cure, so symptoms palliation, quality of life and prolongation of life by a few months are the aims of treatment. So far, gemcitabine monotherapy, and less so its combination with other drugs, was the only accepted treatment worldwide. The limited options were recently enriched, after the results of a large study that demonstrated survival benefit of patients with advanced pancreatic cancer treated with combination of oxaliplatin, irinotecan and 5-fluorouracil, though this regimen was well tolerated only by very fit patients, which is not often the case in this disease [2].

What Did We Learn at the 2011 ASCO Annual Meeting?

Combining Cytotoxics

Firstly, as far as the combination of gemcitabine with other conventional cytotoxics is concerned, Abstracts #4029, #4040 and #4007 address the role of the antimetabolite S-1 in pancreatic cancer. The design of these studies and their results are demonstrated in Table 1 [4, 5, 6].

Commenting on the role of S-1 on the whole after the above results, we could first accept that S-1 is an active fluoropyrimidine in pancreatic cancer which is not inferior to gemcitabine; so, S-1 could be another option. Furthermore, the combination of gemcitabine with S-1 offered a better quality of life than single agent gemcitabine or S-1. Nevertheless, the design of these studies does not answer definitely whether the combination is indeed better than monotherapies, thus more research is needed. We would suggest that since S-1 is only available in Japanese patients, and we often see racial and interethnic genomic differences, the results should be reproduced to other continents as well.
**Table 1.** First line pancreatic cancer trials of gemcitabine and S-1.

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Trial design</th>
<th>No. of patients</th>
<th>Treatment arms</th>
<th>Endpoints</th>
<th>Results</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>#4029 (4)</td>
<td>Omu et al. (Japan)</td>
<td>117</td>
<td>Gemcitabine + S-1 vs. Gemcitabine</td>
<td>Primary: Overall response rate</td>
<td>3.4% vs. 22.6% a</td>
<td>0.0029</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: - Disease control rate</td>
<td>44.1% vs. 60.4% a</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Progression free survival</td>
<td>4.9 vs. 8.0 months a</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Overall survival</td>
<td>7.9 vs. 13.0 months a</td>
<td>0.04</td>
</tr>
<tr>
<td>#4040 (5)</td>
<td>Isayama et al. (GEMSAP study)</td>
<td>106</td>
<td>Gemcitabine + S-1 vs. Gemcitabine</td>
<td>Primary: Progression free survival</td>
<td>3.6 vs. 5.4 months a</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Overall survival</td>
<td>8.8 vs. 13.5 months a</td>
<td>0.104</td>
</tr>
<tr>
<td>#4007 (6)</td>
<td>Ioka et al. (Japan)</td>
<td>834</td>
<td>Gemcitabine + S-1 vs. S-1 vs. Gemcitabine</td>
<td>Primary: Overall survival</td>
<td>10.1 months (G+S-1) vs. 8.8 months (G)</td>
<td>0.1496 b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary: Overall response rate</td>
<td>29.3% (G+S-1) vs. 21.0% (S-1) vs. 13.3% (G)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Progression free survival</td>
<td>5.7 months (G+S-1) vs. NR (S-1) vs. 4.1 months (G)</td>
<td>0.0001 b</td>
</tr>
</tbody>
</table>

a Gemcitabine vs. Gemcitabine + S-1, respectively
b P values of Gemcitabine + S-1 (G+S-1) and S-1 vs. Gemcitabine (G)

**Targeting the Epidermal Growth Factor and Insulin Growth Factor-1 Pathways**

Based on the modest clinical benefit, but statistically significant, by adding erlotinib to gemcitabine, a new phase II study was presented at the ASCO 2011 Annual Meeting exploring the benefit of dual epidermal growth factor receptor (EGFR) inhibition by combining erlotinib, panitumumab and gemcitabine (Abstract #4030) [7]. There was a significant improvement in overall survival by 4.4 months (8.4 vs. 4.0; P=0.077) though there was also a very high increase in non-hematological toxicity (61% vs. 30%). The study met its primary endpoint, thus combining panitumumab, gemcitabine, and erlotinib may be a useful option in pancreatic cancer providing the result will be confirmed in a large randomized phase III study and some kind of biomarker will select patients most likely to respond and tolerate this regimen (K-ras studies are ongoing).

Other biological tested in this setting, are agents targeting the insulin growth factor-1 (IGF-1) pathway which is often upregulated in pancreatic cancer. IGF receptor-1 (IGFR-1) antibodies such as the MK0646 and ganitumab were tested. With regards to MK0646, it was shown in a phase II, three-arm study that combination of MK0646 with gemcitabine produced a higher progression free survival rate as compared to MK0646-gemcitabine-erlotinib or gemcitabine-erlotinib, and a satisfactory partial response rate 20% (vs. 25% and 10%, respectively) though there were no differences in overall survival between arms (Abstract #4026) [8].

Ganitumab, a fully human IGFR-1 antibody, showed in a phase II study (Abstracts #4049 and #4041) that can increase the efficacy and survival of patients with advanced pancreatic cancer when combined to gemcitabine, therefore the ongoing phase III GANP3 study will define its exact benefit in this disease[9, 10].

**Gemcitabine with Other Novel Molecular Agents in Phase I/II Level**

More research on biological agents is ongoing. There were quite a few phase I studies that tested the safety and tolerability of various agents targeting molecules overexpressed in pancreatic cancer in combination with gemcitabine, listed in Table 2 [11, 12, 13].

Apart from the phase I/II studies listed in Table 2, it would be worth mentioning the phase Ib study that...
evaluated the hedgehog pathway inhibitor IPI-926 in combination with gemcitabine (Abstract #4114) [14]. The hedgehog ligand is produced by cancer stromal cells and contributes to the hedgehog signaling (by interacting with patched and smoothened molecules) which regulated stroma and tumor microenvironment and plays role in tumor growth and survival (Figure 1). IPI-926 is an oral small molecule antagonist of smoothened protein. This study demonstrated the combination of IPI-926 with gemcitabine was safe and well-tolerated. Dosing of IPI-926 ranged from 110 mg to 160 mg, with partial responses observed at each of them (a total of 31% of patients demonstrated radiological partial response and 50% of patients a decrease of CA 19-9 by more than 50%). Based on these finding a phase II study testing IPI-926 160 mg with gemcitabine is now actively recruiting patients and the results will be much anticipated. Unfortunately, but not unexpectedly, the combination of sorafenib with gemcitabine, showed no survival benefit in a phase III study (Abstract #4028) [15].

Discussion

The progress in the treatment of pancreatic cancer has been disappointing for many decades. We still observe our patients passing away quite early after the diagnosis, without having improved much of their suffer. Despite this groom reality, there is a sense of change in the air. First, with the fact that drugs other than gemcitabine, such as the combination of 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), can significantly improve survival, especially in a subgroup of very fit patients. Second, with the evidence presented above that S-1, is equal to gemcitabine, at least at the Japanese population that it was tested, and the two drugs may well combine together with some improvement of results. We may acknowledge that while most of the novel agents that initially excite us, they prove at the end less effective in the clinical setting, it is important to explore the molecular basis of the disease and the reasons which lie behind progression and drug resistance. Therefore, from the many targeted agents that are presented here, it seems that the most promising might be the hedgehog inhibitor IPI-926 which aims to block processes at the stroma microenvironment related to angiogenesis, disease progression and refractoriness to treatment. Hopefully, we may find at the near future the effective treatment which has also to be cost-effective in order to allow use it broadly.

Conflict of interest

The authors declare no conflicts of interest

References


